Access to Medicines Tracker

Each quarter, we monitor the progress of our generic partners in developing, filing and selling MPP’s licensed medicines, in countries where access could not have been possible without our work.

To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19 and 12 COVID-19 technologies. 56 generic manufacturers and product developers have now signed MPP sublicensing agreements.

Overview of all licensing and sublicensing agreements

Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 49.71 million patient-years of HIV and hepatitis C products, saving international procurers USD 920 million (January 2012-December 2020).

A slide deck highlighting progress of MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines, is available. It is updated twice a year (last update: April 2022 – data as of December 2021)

Download the slide deck (PDF)


Interactive map:
– Patent and licensing status: last updated on 11 May 2021;
– Product availability data from MPP sublicensees: last updated in June 2022 (data as of 31 March 2022).

Last update of the interactive table in June 2022 (data as of 31 March 2022).

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Disclaimer: The information presented on the interactive map below, under the “Patent and licensing status” filter, is sourced from MPP’s patent and licensing database, MedsPaL. Users should NOT consider MedsPaL a complete and authoritative source of patent information, and it is not meant to provide a ‘freedom-to-operate’ analysis. It only provides a snapshot at a point in time, based on the information available to us.

We do not accept any legal responsibility for the accuracy of data. In particular, we do not guarantee it is complete, up to date or fit for specific purposes. Users should undertake additional country search and legal analysis before making any procurement or business decision.